Skip to main content
Kintor Pharmaceutical Limited logo

Kintor Pharmaceutical Limited — Investor Relations & Filings

Ticker · 9939 HKEX Manufacturing
Open in API
Filings indexed 312 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country HK Hong Kong
Listing HKEX 9939

About Kintor Pharmaceutical Limited

http://www.kintor.com.cn

Kintor Pharmaceutical Limited is a clinical-stage novel drug developer specializing in the research and development of innovative small molecule and biologic therapeutics. The company focuses on addressing substantial unmet medical needs within dermatology and oncology, with a particular emphasis on androgen receptor (AR)-related diseases. Kintor maintains a robust, multi-channel pipeline featuring proprietary technologies such as AR antagonists, AR-PROTACs, mTOR inhibitors, and the licensed ALK-1 antibody project. Key therapeutic targets include hair loss (AGA), acne, prostate cancer, and liver cancer. The company utilizes a global integrated R&D platform to develop combination therapies and has initiated commercialization efforts for cosmetic treatments derived from its pipeline.

Recent filings

Filing Released Lang Actions
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025
Regulatory Filings
2026-04-29 English
ANNUAL REPORT 2025
Regulatory Filings
2026-04-29 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
Regulatory Filings
2026-04-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly listing rule return (Form FF301) submitted to the Hong Kong Exchange under Chapter 19B, detailing authorised share capital, issued shares, treasury shares and public float sufficiency. It is not an earnings release, annual report, capital raising announcement, nor a meeting or voting document. There is no specific category for monthly listing returns, so the appropriate classification is the fallback “Regulatory Filings” (RNS).
2026-04-01 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is an “Annual Results Announcement for the Year Ended 31 December 2025” filed on the Hong Kong Stock Exchange, containing financial highlights, loss/profit figures, business highlights, and Management Discussion & Analysis. It constitutes the initial announcement of annual financial results rather than the full annual report. This matches the definition of an Earnings Release (ER). FY 2025
2026-03-30 English
POSTPONEMENT OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a short announcement (1,626 characters) notifying the market of a postponement of the company’s board meeting date. It does not contain financial results, report content, dividend details, a full annual/interim report, or any management/board composition changes. It simply informs of a corporate scheduling event and does not fit any more specific category. Therefore, it is best classified under the fallback “Regulatory Filings (RNS)” for miscellaneous regulatory announcements.
2026-03-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.